Referral Center for Pediatric Gastroenterology and Nutrition, Children's Hospital Zagreb, Zagreb, Croatia; University of Zagreb, School of Medicine, Zagreb, Croatia; University J.J. Strossmayer, School of Medicine, Osijek, Croatia.
University of Zagreb, School of Medicine, Zagreb, Croatia.
Clin Nutr. 2020 Apr;39(4):1108-1111. doi: 10.1016/j.clnu.2019.04.015. Epub 2019 Apr 17.
BACKGROUND & AIMS: This study aimed to evaluate the effect of the route of exclusive enteral nutrition (EEN) delivery (orally or via nasogastric (NG) tube) and type of polymeric formula (with taste vs tasteless and isocaloric vs hypercaloric) on the disease outcome and nutritional status in children with Crohn's disease (CD).
This was a single center retrospective study which included all CD patients whose active disease at diagnosis was treated with EEN in the period from October 2007 to November 2017. All patients received polymeric formula orally or through a NG tube, which was based on the physicians and child's preference.
A total of 92 CD patients were included in the study (mean age 13.6 ± 3.0 years; 45.7% female). Overall, 42 (45.7%) patients received EEN via NG tube until the end of the EEN period. Remission was achieved in 71 (77.2%) children. There was no difference in the EEN failure status, remission duration, inflammatory markers, and weight gain at the end of the EEN period between oral intake and NG tube groups. None of the factors including age, disease location, type of formula (with taste vs tasteless and isocaloric vs hypercaloric) and mode of delivery (orally vs through NG tube for the whole duration of EEN) demonstrated an association with EEN failure.
This study failed to demonstrate an effect of the route of EEN delivery and the characteristics of the polymeric formula on the outcome of treatment in pediatric patients with CD.
本研究旨在评估肠内营养（EEN）的给予途径（口服或经鼻胃管）和聚合配方类型（有味道与无味道、等热量与高能量）对儿童克罗恩病（CD）患者疾病结局和营养状况的影响。
这是一项单中心回顾性研究，纳入了 2007 年 10 月至 2017 年 11 月期间接受 EEN 治疗的所有初诊时处于活动期的 CD 患者。所有患者均接受口服或经鼻胃管给予聚合配方，具体途径基于医生和患儿的偏好。
本研究共纳入 92 例 CD 患者（平均年龄 13.6±3.0 岁；45.7%为女性）。总体而言，42 例（45.7%）患者经鼻胃管给予 EEN 直至 EEN 结束。71 例（77.2%）患儿实现缓解。口服组和经鼻胃管组在 EEN 失败状态、缓解持续时间、炎症标志物和 EEN 结束时的体重增加方面无差异。包括年龄、疾病部位、配方类型（有味道与无味道、等热量与高能量）和给予途径（整个 EEN 期间口服或经鼻胃管）在内的任何因素均与 EEN 失败无关。
本研究未能证明 EEN 给予途径和聚合配方特征对 CD 患儿治疗结局有影响。
